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The 2012Nobel Prize in Chemistry has been awarded to Brian K. Kobilka andRobert J. Lefkowitz for
their studies of G-protein-coupled receptors. Their pioneering work over the past 40 years has
provided detailed molecular insight into the structure and function of this fundamentally important
family of receptors.The Early Years of GPCR
Biochemistry
The idea of receptors began in the early
20th century, and it was J.N. Langley
who first raised the concept of a ‘‘recep-
tive substance’’ on cells to explain the
ability of drugs to regulate neuromuscular
transmission. As late as 1973, however,
several noted pharmacologists such as
Ahlquist and Sutherland remained skep-
tical as to whether such receptors actually
existed as distinct entities. During this
period of skepticism, Robert Lefkowitz
became interested in receptor biology,
and this interest would drive his entire
scientific career. Lefkowitz received his
MD from Columbia in 1966; subsequently
moved to the NIH to train with Jesse Roth
and Ira Pastan and then to Mass General,
where he worked with Ed Haber; and also
received residency training in cardiology.
During this training period, Lefkowitz
developed one of the first radioligand
binding assays for a G-protein-coupled
receptor (GPCR), the adrenocorticotropic
hormone (ACTH) receptor, in the Pastan
and Roth labs and also studied the
binding of catecholamines to cardiac
tissue with Haber. Lefkowitz moved to
Duke University in 1973 to take his first
faculty position. There, together with one
of his first trainees and now long-time
colleague Marc Caron, as well as other
trainees in the lab, he set about devel-
oping the biochemical techniques needed
to study b-adrenergic receptors (bARs).
His rationale at the time for studying the
bAR was that it was of physiological
importance to cardiovascular function, it
activated the enzyme adenylyl cyclase,
and there were many bAR agonists and1148 Cell 151, December 7, 2012 ª2012 Elseantagonists available to facilitate bio-
chemical analysis of the receptor.
This early work included the develop-
ment of a specific radioligand binding
assay to enable the measurement of
bAR-binding sites in cells and tissues
(Lefkowitz et al., 1974), the identification
of detergents to successfully solubilize
a functional bAR from membrane prepa-
rations (Caron and Lefkowitz, 1976), and
the synthesis of an affinity resin and pho-
toaffinity ligands to facilitate receptor
purification (Caron et al., 1979). The
development of these techniques enabled
the subsequent purification of the b2AR
initially from frog erythrocytes in 1981
and then from mammalian sources such
as hamster lung. Moreover, comparable
techniques were developed in the Lefko-
witz lab for purification of the other three
then known adrenergic receptor subtypes
(b1AR, a1AR, and a2AR). It is important to
note that these receptors are found at
exceedingly low levels in most tissues
and required 100,000-fold purification
to fully isolate. Subsequent studies recon-
stituted the purified b2AR into phospho-
lipid vesicles and provided the first
demonstration that the isolated receptor
could effectively couple agonist binding
to activation of the heterotrimeric G
protein Gs and subsequent activation of
adenylyl cyclase to produce cAMP (Cer-
ione et al., 1984). Another important appli-
cation of the ligand binding methods led
to the development of the ‘‘ternary
complex model,’’ which proposed that
high-affinity agonist binding was the
result of an agonist-receptor-G-protein
complex—results beautifully visualized
30 years later by the agonist-b2AR-Gsvier Inc.structure from the Kobilka lab. Thus, the
early work of Lefkowitz laid the ground-
work for the biochemical characterization
of GPCRs and demonstrated that the
b2AR exists as a distinct protein entity
that binds ligands and couples ligand
binding to activation of heterotrimeric G
proteins.
Cloning Reveals a Family of GPCRs
The stage for the cloning of the b2AR and
other adrenergic receptors was largely set
by the focus of the Lefkowitz group
on receptor purification. The purified
hamster b2AR ultimately provided the first
sequence of several peptides that were
then used to synthesize oligonucleotides
for cloning studies. Importantly, this
work involved collaboration between the
Lefkowitz group and a group from Merck
Sharp & Dohme, with initial cloning efforts
being coordinated by Richard Dixon at
Merck. Brian Kobilka, a cardiology fellow
who joined the Lefkowitz lab in 1984,
was also involved in this project, and
when cDNA library screening proved
unsuccessful, he decided to generate
a hamster genomic library. Subsequent
screening of this library by Kobilka and
Dixon ultimately yielded the gene encod-
ing the b2AR, which was then used to
isolate a b2AR cDNA (Dixon et al., 1986).
There were two surprising features of the
b2AR gene. First, the gene was intronless.
At the time, this was somewhat heretical,
although this has proven to be a common
feature of many GPCR genes. Second,
and even more surprising, was that the
amino acid sequence of the b2AR had
significant homology with rhodopsin,
the receptor for light that had been
independently sequenced by the Ovchini-
kov and Hargrave groups in 1982 and
cloned by Nathans and Hogness in
1983. This finding provided the first
insight that rhodopsin and the b2AR
were members of a family of GPCRs that
would likely have similar structures.
Indeed, as noted by the authors in their
publication, ‘‘the amino-acid sequence
predicted for the bAR indicates significant
amino-acid homology with bovine rho-
dopsin and suggests that, like rhodopsin,
bAR possesses multiple membrane-
spanning regions’’ (Dixon et al., 1986).
Though this finding makes sense in retro-
spect, no one at that time had envisioned
that visual and hormonal receptors would
have any homology. This discovery was
confirmed several months later by Ross
and Ulrich, who cloned a cDNA for the
avian b1AR, and by Numa and coworkers,
who cloned the gene for a porcinemusca-
rinic acetylcholine receptor. Moreover,
the Lefkowitz group also went on to
rapidly clone additional GPCRs, including
seven of the remaining eight adrenergic
receptors, as well as the 5HT1A receptor.
Kobilka played a major role in cloning
five of these receptors and also devel-
oped a novel b2AR/a2AR chimeric re-
ceptor approach to start to dissect the
domains involved in ligand binding and
G protein coupling (Kobilka et al., 1988).
Taken together, this body of work pro-
vided the first fundamental insight into
the structural similarities in the super-
family of GPCRs, which now numbers
800 in humans.
Regulation of GPCR Function
Another major area of investigation in the
Lefkowitz lab during the 1980s focused
on understanding the mechanisms
involved in receptor desensitization. This
line of investigation was being carried
out simultaneously with the receptor puri-
fication and cloning efforts and demon-
strated that the b2AR underwent rapid
agonist-promoted phosphorylation and
internalization. These studies also led to
the surprising revelation that the structural
similarities observed between the b2AR
and rhodopsin also extended to the
mechanisms that regulate the signaling
of these two receptors. The first insight
into this similarity was provided by the
identification of a protein kinase called
the b-adrenergic receptor kinase (nowknown as GRK2), which was found to
phosphorylate the b2AR in an agonist-
dependent manner (Benovic et al.,
1986). This observation was strikingly
similar to the phosphorylation of light-
activated rhodopsin by the enzyme
rhodopsin kinase (now known as GRK1),
which had been previously identified.
Indeed, additional studies demonstrated
that each kinase could phosphorylate
each other’s preferred substrate, albeit
to a significantly reduced extent (e.g.,
GRK2 preferred the b2AR over rho-
dopsin, whereas GRK1 preferred rho-
dopsin over the b2AR). The subsequent
cloning of GRK2 revealed it to be the
first cloned member of a family of kinases
that now numbers seven (Benovic et al.,
1989). Another striking similarity observed
by the Lefkowitz group between the
regulation of visual and hormonal
signaling involved the role of the protein
arrestin. Arrestin was initially identified
as a protein in rod cells that could bind
to activated phosphorylated rhodopsin
and effectively quench phototransduc-
tion. Initial studies on the b2AR suggested
the involvement of an arrestin-like protein
in the desensitization process, and sub-
sequent cloning efforts identified a nonvi-
sual arrestin termed b-arrestin (Lohse
et al., 1990). Thus, these studies revealed
significant conservation in the mecha-
nisms that regulate visual and hormonal
signaling.
Understanding the mechanisms in-
volved in regulating GPCR signaling has
remained a major focus of the Lefkowitz
group over the past 20–25 years. Their
work has provided important mechanistic
understanding into the dynamics of GRK
and b-arrestin function, with a major
current emphasis involving the develop-
ment of biased agonists that have
the ability to promote selective interaction
of a given GPCR with G proteins, GRKs,
or b-arrestins (Whalen et al., 2011). This
line of investigation has the promise to
lead to the development of improved
GPCR therapeutics with reduced side
effects.
GPCR Structure
In 1989, toward the end of the GPCR
cloning efforts in the Lefkowitz lab, Ko-
bilka moved to Stanford University. He
initially focused his research efforts in
twomajor areas. One involved developingCell 151, Dknockout mice to better understand the
physiological role of the adrenergic
receptors, and the other involved the use
of biophysical strategies to better under-
stand the structural dynamics of the
b2AR, with an ultimate goal of crystallizing
the receptor. Although significant insight
was gained from the biophysical work in
the Kobilka lab, it was Palczewski and
coworkers who provided the first glimpse
of a GPCR structure by solving the X-ray
crystal structure of rhodopsin at 2.8 A˚
resolution (Palczewski et al., 2000). This
work not only provided important insight
into the structure of rhodopsin in its basal
state but also clearly proved that such
complex membrane proteins could be
crystallized. At this point, the Kobilka
group had been working on developing
methods to crystallize the b2AR for some
10 years and had made significant prog-
ress but had no crystals in hand. The
major approaches being used to facilitate
crystallization included alanine scann-
ing mutagenesis for thermostabilization,
use of inverse agonists to stabilize the
protein in a basal state analogous to
rhodopsin, and the development of anti-
body fragments that could bind to the
intracellular domains of the receptor and
help stabilize the conformation. These
strategies, in combination with lipid-medi-
ated screening and the use of microfocus
diffraction techniques, ultimately contrib-
uted to the first reported X-ray structure
of the b2AR (Rasmussen et al., 2007).
This 3.4 A˚ resolution structure provided
insight into the transmembrane domains
and intracellular portions of the receptor,
although the extracellular regions were
not visible. Another approach being
used by the Kobilka group involved engi-
neering lysozyme into the third intracel-
lular loop of the receptor (Rosenbaum
et al., 2007). This strategy ultimately re-
sulted in a 2.4 A˚ high resolution structure
of the b2AR that was published 1 week
after the initial Rasmussen work (Che-
zerov et al., 2007). Indeed, the engi-
neering of lysozyme into GPCRs has
proven to be a panacea for crystallizing
and solving GPCR structures. Another
key ingredient in solving these initial
structures involved the collaborations
that Kobilka developed with outstanding
crystallographers, including Ray Stevens
at Scripps, Bill Weis at Stanford, and
Gebhard Schertler at theMRC Laboratoryecember 7, 2012 ª2012 Elsevier Inc. 1149
Figure 1. Structure of an Active b-Agonist-b2AR-Gs Complex
Ribbon diagrams of inactive b2AR (turquoise) with bound inverse agonist and
Gas (brown) with bound GTPgS are shown on the left. A complex between
b-agonist (dark blue), b2AR, and Gs (Ga, Gb [pink], and Gg [red]) is shown on
the right (Rasmussen et al., 2011). Major conformation changes occurring in
the b2AR upon activation include lengthening of TM5 by two helical turns
and a 14 A˚ outward movement of TM6. Changes in Gas include displacement
of the a-helical domain (GaAH) to promote GDP dissociation andmovement of
the Ga5 helix to mediate receptor binding. The GaRas domain of Gas is also
noted.of Molecular Biology. Kobilka
and Weis have now teamed
up to solve the structures of
many GPCRs, including the
agonist-bound b2AR, a nano-
body-bound b2AR in an active
conformation, the M2 and
M3 muscarinic acetylcholine
receptors, and the m- and
d-opioid receptors. The Ste-
vens group has also solved
many additional GPCR struc-
tures, including the A2A
adenosine, CXCR4, D3 dopa-
mine, H1 histamine, sphingo-
sine 1-phosphate, and k-
opioid. Solving GPCR crystal
structures seems almost
routine now, though the 15
years that it took Kobilka to
obtain the initial X-ray struc-
ture of the b2AR was a true
test of perseverance.
Although the successful
crystallography of GPCRs
over the past 5 years has
been a stunning achievement,
what proved to be the icing on
the cake was the elegant
structure of an agonist-
b2AR-Gs complex reported
by Rasmussen, Sunahara,Kobilka, and coworkers in 2011 (Rasmus-
sen et al., 2011) (Figure 1). Indeed, the
press release for the 2012 Nobel Prize in
Chemistry ended with the statement,
‘‘Kobilka and his research team captured
an image of the b-adrenergic receptor at
the exact moment that it is activated by
a hormone and sends a signal into the
cell. This image is a molecular master-
piece—the result of decades of
research.’’ The pioneeringwork of the Lef-
kowitz and Kobilka laboratories over the
past 40 years has provided a tremendous
understanding of how this fundamentally
important family of receptors function
and is indeed a molecular masterpiece.1150 Cell 151, December 7, 2012 ª2012 ElseACKNOWLEDGMENTS
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